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Target selection and prioritization are common goals for 
academic and commercial drug research organizations. 
While motivations differ, in all cases, the target selection 
task is fundamentally one of resource allocation in the 
face of incomplete information. Consequently, target 
selection strategies (and metric-based approaches to 
assess their success) remain complex1 and are hindered 
by multiple bottlenecks. Some bottlenecks pertain to the 
data themselves, such as disjointed, disparate data and 
metadata standards, data recording errors and accessi-
bility issues; overcoming these issues will require human 
and computational efforts and coordination across mul-
tiple communities. Another set of bottlenecks pertains to 
the scientists involved. These include a tendency to focus 
on a small subset of well-known genes2 and the tendency 
to avoid riskier research paths, driven by poor research 
funding climates3.
For the purposes of this article, we define knowledge 
as the consensus of information aggregated from dif-
ferent sources and information as structured data, with 
a contextual layer that supports a broad range of data 
analytics. Data have quantity, quality and dimensionality 
(for example, genomic knowledge is defined in relation 
to associations with distinct entities such as molecular 
probes and disease concepts). Data, like facts, may also 
have an expiration date (Supplementary Box S1), and 
thus knowledge is subject to change. Yet, within a given 
time frame, knowledge provides context for interpre-
tation and integration of emergent data, information 
and models.
Data-driven drug discovery strategies rely on the 
integration of proprietary and internal data with 
third-party resources — both public databases, such 
as PubMed, PubChem4, ChEMBL5 and The Cancer 
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Drug
Externally administered, 
possibly endogenous but 
mostly xenobiotic, substances 
that are administered to 
patients in order to influence 
the outcome of a disease, 
syndrome or condition.
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Abstract | A large proportion of biomedical research and the development of therapeutics is 
focused on a small fraction of the human genome. In a strategic effort to map the knowledge gaps 
around proteins encoded by the human genome and to promote the exploration of currently 
understudied, but potentially druggable, proteins, the US National Institutes of Health launched 
the Illuminating the Druggable Genome (IDG) initiative in 2014. In this article, we discuss how the 
systematic collection and processing of a wide array of genomic, proteomic, chemical and 
disease-related resource data by the IDG Knowledge Management Center have enabled the 
development of evidence-based criteria for tracking the target development level (TDL) of 
human proteins, which indicates a substantial knowledge deficit for approximately one out of 
three proteins in the human proteome. We then present spotlights on the TDL categories as well 
as key drug target classes, including G protein-coupled receptors, protein kinases and ion 
channels, which illustrate the nature of the unexplored opportunities for biomedical research 
and therapeutic development.
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Drug targets
Molecular entities present in 
living systems that, upon 
interaction with therapeutic 
agents or their by-products, 
result in modified biological 
responses that lead to 
therapeutic outcomes. The 
interaction between a drug and 
its target leads, directly or 
indirectly, to observable clinical 
outcomes.
Druggable genome
Originally defined by Hopkins 
and Groom as the set of genes 
that encode proteins that 
could be modulated by an 
orally administered small 
molecule, as estimated by 
Lipinski’s ‘rule of five’ 
guidelines.
Genome Atlas (TCGA6), and commercial databases, 
such as Integrity. This integration requires fusion and 
reconciliation of heterogeneous and sometimes con-
flicting data sources and types. Although many of 
these resources are already partially interlinked, data 
heterogeneity, complexity and incompleteness, as well 
as contextual information and metadata capture, pose 
substantial barriers to reliable systematic analyses of all 
data required to address biomedical research questions, 
such as target prioritization in drug discovery1.
With the increasing scale and variety of data genera-
tion, collection and curation in the biomedical sciences, 
there is an unmet need for in-depth, accurate and truth-
ful integration of multiple scientific domains across 
disciplines. Once successful, these data and knowledge 
integration efforts enable us to ask both global and 
fundamental questions about genes, proteins and the 
processes they are involved in. Integrated resources also 
allow us to address aspects of reproducibility7 via con-
cordance of similar data types from unrelated sources 
and deficits in our knowledge of biological systems 
and their function. More generally, data integration 
facilitates our ability to quantify knowledge using an 
evidence-based approach.
Illuminating the Druggable Genome. “The reluctance 
to work on the unknown” (REF.  2) is inherent to the 
scientific endeavour, partly due to our subconscious 
tendency to choose research subjects more likely to 
confirm what we already know or believe8. In a deliber-
ate, strategic attempt to map the knowledge gaps around 
potential drug targets and to prompt exploration of cur-
rently understudied but potentially druggable proteins, 
the US National Institutes of Health (NIH) launched the 
Illuminating the Druggable Genome (IDG) initiative in 
2014. As part of this broad, multimillion-dollar initiative, 
the IDG Knowledge Management Center (KMC) aims 
to systematize general and specific biomedical knowl-
edge by processing a wide array of genomic, proteomic, 
chemical and disease-related resources (BOX 1), with the 
explicit goal of supporting target hypothesis genera-
tion and subsequent knowledge creation, especially for 
genes and proteins that are not well studied.
In this article, we first define objective, evidence-based 
criteria for tracking target development levels (TDLs) for 
human proteins, using multiple sets of current knowl-
edge. We discuss the data collected by the KMC on 
TDLs, which show the existence of a substantial knowl-
edge deficit concerning a large portion of the human 
proteome (one out of three proteins). Reflecting the goal 
of illuminating the druggable genome, we then present 
spotlights on the TDL categories, as well as on key target 
classes, including G protein-coupled receptors (GPCRs), 
protein kinases and ion channels.
Knowledge-based protein classification
Target development levels. Most current protein clas-
sification schemes are based on structural and func-
tional criteria. For any given protein, it is also possible 
to identify associated drugs and chemical or biologic 
modulators, and many types of experimental data can be 
associated with the protein, including publications, pat-
ents, gene expression data and experimental or modelled 
3D structures.
For target prioritization and therapeutic development, 
it is useful to understand the quantity and diversity of 
data that are available for a given protein and to assign 
a qualitative knowledge metric that characterizes the 
degree to which a target is comparatively well studied or 
unstudied. To address this, we developed the TDL clas-
sification scheme, which categorizes proteins into four 
groups — Tclin, Tchem, Tbio and Tdark — with respect to the 
depth of investigation from a clinical, chemical and bio-
logical standpoint (FIG. 1; TABLE 1). Except for Tclin, TDL 
assignments were performed without human curation. 
Formal definitions for the TDL categories are as follows.
• Tclin (clinic) proteins are drug targets linked to at least 
one approved drug (that is, an active pharmaceuti-
cal ingredient) by mechanism of action (MoA) (this 
criterion supersedes any of the other parameters). 
Classification into this TDL category was achieved 
through exhaustive manual querying of primary lit-
erature and drug labels for MoA assignments with 
respect to molecular (protein) targets9; drug targets 
annotated as MoA-related proteins are categorized as 
Tclin (see further discussion below).
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• Tchem (chemistry) proteins lack MoA-based links to 
approved drugs but are known to bind to small mole-
cules with high potency. The interactions between pro-
teins and small molecules (and sometimes approved 
drugs) are usually studied in the context of a disease 
and often arise from medicinal chemistry efforts. For 
inclusion in the Tchem category, we required the bio-
activity of at least one small molecule to be above a 
specific cut-off chosen to include about 90% of the 
bioactivity values of drugs with a confirmed MoA 
for a target from that protein family (Supplementary 
Figure S2). Currently chosen thresholds are ≤30 nM 
for kinases, ≤100 nM for GPCRs and nuclear recep-
tors, ≤10 μM for ion channels and ≤1 μM for other 
target families. Bioactivity values were extracted from 
ChEMBL5 and DrugCentral10.
• Tbio (biology) refers to those proteins that have a con-
firmed Mendelian disease phenotype in the Online 
Mendelian Inheritance in Man (OMIM) database11 
(that is, at least two publications), have Gene Ontology 
(GO)12 leaf term annotations based on experimental 
evidence or meet two of the following three condi-
tions: a fractional PubMed publications count13 above 
five; three or more National Center for Biotechnology 
Information (NCBI) Gene Reference Into Function 
(RIF) annotations; or 50 or more commercial anti-
bodies, counted from data made available by the 
Antibodypedia database14. Tbio assignments imply 
that these proteins are not MoA-related drug targets 
(these are Tclin proteins). However, it does not follow 
that these proteins lack associations with bioactive 
molecules, including approved small-molecule drugs 
and biologics. It does, however, imply that given cur-
rent levels of evidence, associated bioactivity values 
and clinical observations did not meet Tchem or Tclin 
criteria, respectively.
• Tdark (dark genome) refers to the remaining proteins 
that have been manually curated at the primary 
sequence level in UniProt15 yet do not meet any of 
the criteria for Tclin, Tchem or Tbio. Even for this cate-
gory, evidence may be available concerning genome-
wide association studies (GWAS), tissue location, 
dysregulation, inferred function via homology, etc. 
Many proteins in the Tdark category are not context-
less sequences. However, these are proteins for which 
there is the least current knowledge and a low number 
of specific molecular probes available, and some rep-
resent unexplored opportunities within the druggable 
human genome. While evidence that approved drugs 
interact with some Tdark proteins may be available, the 
above criteria were observed for all Tdark assignments 
(Supplementary Table S3).
The knowledge deficit. FIGURE 2a summarizes the vary-
ing degree of available data (represented using a normal-
ized count of occurrence) for seven different data types 
associated with individual targets and grouped by TDL. 
The first three groups illustrate category differences for 
three TDL defining criteria discussed above — namely, 
the fractional count of protein and/or gene mentions in 
PubMed abstracts, NCBI Gene RIF counts and antibody 
counts per protein. ‘GO terms’ examines the distribution 
of GO12 annotation counts per protein using data from 
UniProt15. ‘R01 grants’ examines the distribution of text-
mined R01 grant counts detected for each protein using 
NIH RePORTER data (see below for further discus-
sion). ‘Patents’ examines the distribution of text-mined 
granted patents for each protein using SureChEMBL16 
data. Finally, the data availability score summarizes 
experimental information density per protein obtained 
from Harmonizome17 data — a resource developed 
independently for the KMC that provides an abstract 
representation of the many types of data associated 
with all human genes and proteins (BOX 1).
Whereas the first three data types were used to assign 
the TDL category for proteins in the Tbio and Tdark catego-
ries, the other four data types — derived from separate text 
corpora and repositories — provide independent valida-
tion of our criteria for categorization overall. Distribution 
trends within TDL categories are consistently repro-
duced across all data types in FIG. 2a and have statisti-
cally significant differences (Supplementary Table S4). 
Tdark proteins have the least amount of data associated 
with them regardless of source.
Increasing amounts of data are observed for proteins 
when progressing through the categories from Tdark to 
Tbio, Tchem and Tclin. For example, Tdark proteins tend not 
to be the object of study for many funded NIH R01 grants 
and are significantly less discussed in patents compared 
with proteins in other TDLs. Statistical significance 
breaks down when comparing Tclin and Tchem, but because 
successful clinical trials are required for the Tchem-to-Tclin 
progression, this evidence may not be well captured by the 
four data types highlighted in Supplementary Table S4. 
However, this is less surprising from a knowledge man-
agement perspective, since on average, the biochemis-
try and pharmacology of a protein are likely to be well 
studied upon reaching the Tchem development stage. It is 
important to note that the Tchem stage can be completely 
bypassed for targets of therapeutic antibodies and 
other biologics.
In summary, all the data, information and knowl-
edge aggregated and processed within the IDG KMC 
archive (partially illustrated in FIG. 2a) confirm the 
existence of a knowledge deficit about many proteins, 
some of which could have therapeutic relevance. The 
bias towards well-described proteins2 is confirmed not 
only with respect to publications but also with respect 
to patents, NIH funding patterns, GWAS and mouse 
phenotype data (data not shown), availability of molec-
ular probes such as antibodies and small molecules, and 
even queries in the STRING18 database (see below and 
FIG. 2b). Because of this bias, one out of three human 
proteins (Tdark) have been largely unstudied. Although 
the NIH acknowledged that illumination should directly 
target understudied proteins, scientists engaged in target 
selection are likely to remain risk-averse and perhaps 
systematically less inclined to study Tdark proteins.
Our classification provides overall insight into the 
current illumination levels and sizes the opportunity 
for drug targets from well-established and precedented 
druggable protein families. The natural progression is for 
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Mode of action
Referred to as ‘mechanism of 
action’ when the molecular 
interactions are well 
understood; describes the way 
in which drugs exert their 
intended therapeutic action, 
resulting in the intended 
therapeutic outcome.
proteins of potential therapeutic interest to migrate from 
Tdark to Tclin over time, and TDL monitors knowledge 
accumulation using multiple types of clinical, chem-
ical and biological evidence, while providing an easily 
interpretable ranking scheme. We argue that proteins in 
Tdark and Tbio are understudied and more in need of illu-
mination, and we discuss approaches for achieving this 
later in the article, after first overviewing knowledge on 
proteins in the Tclin and Tchem categories.
Spotlight on Tclin and Tchem
Evaluating protein target druggability — the ability of 
a protein to be therapeutically modulated by medicines 
— can involve complex assessments of a range of protein 
characteristics. Structural biology and computational 
and medicinal chemistry assessments of druggability 
largely focus on forecasting whether a target protein can 
bind to drug-like small molecules with high affinity and 
specificity19. However, druggability literature rarely men-
tions biologics, antibodies and other protein therapeu-
tics, radiotherapy (Supplementary Box S5), gene therapy 
or stem cells. In this section, we discuss Tclin and Tchem 
proteins in the context of small-molecule drug discovery.
Tclin proteins. Ideally, unequivocal Tclin assignment (that 
is, identification of molecular drug targets) would require 
several layers of evidence: a full matrix of in vitro bio-
activity for all prodrugs, drugs and active metabolites 
(active ingredients) assayed against all relevant human 
and non-human (for example, bacterial and viral) targets 
Box 1 | Overview of the Illuminating the Druggable Genome Knowledge Management Center
Knowledge management implies the ability to structure data into 
information88 while combining low-volume, high-quality data, such as 
thorough analyses of experimental data (for example, high-resolution 
X-ray crystallographic structures) or evidence-based systematic reviews 
(for example, the Cochrane Collaboration), with high-volume (and perhaps 
lower quality) data such as genome-wide association studies (GWAS) or 
high-throughput screening data sets. As the overall scientific process 
requires the archiving, evaluation and re-interpretation of sometimes 
conflicting data, the Illuminating the Druggable Genome Knowledge 
Management Center (IDG KMC) faces similar challenges. Consensus 
emerges based on repeated independent experiments, robustness of the 
results (for example, modified reagents or conditions, or model organisms), 
increased domain expertise and qualitative judgement. To this end, the 
IDG KMC automates algorithmic processing of structured data by 
extracting and processing expression and functional data related to 
proteins and genes, molecular probes such as small molecules and 
antibodies, small-molecule bioactivities, GWAS, disease associations  
and launched drug information (among other data types) into the Target 
Central Resource Database (TCRD)89. TCRD content is presented via 
Pharos, a multimodal web interface89 (see below).
TCRD–Pharos is not unique in providing integrated content:  
ChEMBL, DrugBank90 and UniProt91 are excellent examples of drug 
discovery integration systems, for example, for chemical structure and 
drug bioactivity data and protein and disease information, largely focused 
on a specific knowledge domain. CiViC92 combines multiple resources with 
a specific goal, for example, to enable clinical interpretation of gene 
variants. The only resource that parallels the scope of IDG KMC is 
OpenTargets93, a consortium focused on disease-specific target validation 
efforts. The KMC collates evidence about all human proteins from multiple 
domains, supporting research on understudied proteins and new biology, 
and includes the following resources.
Target Central Resource Database
TCRD is the central open-access data repository for the IDG KMC and is the 
primary data source for the IDG KMC project-wide web portal Pharos89. 
TCRD integrates 55 heterogeneous data sets, with over 85 million gene  
and/or protein attributes. Special emphasis is placed on four families that 
were of interest to the pilot phase of the IDG programme: G protein-coupled 
receptors, ion channels, kinases and nuclear receptors (TABLE 1). The focus 
on this fraction of the proteome is justified by historical evidence, which 
indicates that these four protein families are among the most consistently 
successful druggable target classes (see also TABLE 2). TCRD is available 
under the CC-BY-SA 4.0 licence. Programmatic access to TCRD is also 
available via a REST application programme interface (API).
Pharos
Access to TCRD content is via the web portal Pharos89, which is a Java 
platform that supports efficient and intuitive search queries and 
browsing of all TCRD data. Features include search filters to reduce lists 
of targets, query-saving capability for sharing, and dossier functionality 
to collate data during searching or browsing. Pharos provides an 
extensive REST API to support programmatic access and inclusion in 
pipelining tools.
Harmonizome
Given the wide variety of experimental data that is generated on 
individual proteins, it is useful to characterize the total availability of data 
types around individual targets. This Harmonizome is a resource 
developed for KMC17 that contains a collection of processed data sets 
from 70 major online resources, abstracted and organized into ~72 million 
functional associations between genes and proteins and their attributes. 
Such attributes could be physical relationships with other biomolecules, 
expression in cell lines and tissues, genetic associations with knockout 
mouse or human phenotypes or changes in expression after drug 
treatment.
These associations are stored in a relational database along with rich 
metadata for genes and proteins, their attributes and the original sources. 
To report overall levels of knowledge for each target, the Harmonizome 
computes a cumulative probability of a protein occurring within a given 
data set. With appropriate normalization, this results in an association 
score for a protein–data source pair, with values ranging from 0 to 1. 
When a source has no data associated with a target, its score is set to 0. 
Currently, 110 individual data sources (including supplementary files from 
publications and public repositories of omics data) are made available 
through the Harmonizome, resulting in a 110-element vector 
representation for each target. From this vector, we compute the data 
availability score as the sum of the 110 association scores.
The Harmonizome is available through a web portal, a web service and  
a mobile app for querying, browsing and downloading all data. The 
Harmonizome visualizes gene–gene and attribute–attribute similarity 
networks for all processed data sets.
DrugCentral
This online compendium provides chemical, pharmacological and 
regulatory information for active pharmaceutical ingredients  
and pharmaceutical products by linking chemical entities, multiple drug 
identification codes, drug mode of action and pharmacological action at 
the target level, and pharmaceutical formulation and product-specific 
information, as well as indications, contraindications and off-label 
indications10. DrugCentral links 4,509 active ingredients to 93,084 
pharmaceutical products and is available under the CC-BY-SA 4.0 licence.
Drug Target Ontology
This is an interactive framework to integrate, navigate and analyse drug 
discovery data, based on formalized and standardized classifications and 
annotations of human proteins94, available under the CC-BY-SA 4.0 
licence.
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(such as the half-maximal inhibitory concentration (IC50), 
effector concentration for half-maximum response (EC50), 
inhibitory constant (Ki) and the dissociation constant 
(Kd)); on–off rate constants and other kinetic measure-
ments performed at appropriately relevant concentra-
tions in the tissue or tissues relevant for that particular 
disease context, preferably with matching in vivo data 
in humanized animal models (although human data are 
preferable); and phenotypic confirmation supported by 
pharmacodynamic data. In animal disease models lacking 
the gene or genes responsible for the MoA of the drug, the 
drug should lack therapeutic effect. Meeting these criteria 
would be needed in order to attribute the desired clinical 
outcome to a specific drug target interaction mechanism.
Nature Reviews | Drug Discovery
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Figure 1 | Target development level categories applied to the human proteome. a | Percentages of the whole 
proteome are shown in the inner ring. Percentages of each target development level (TDL) category for selected major 
protein families are shown in the outer ring, with the Tclin category expanded. Inner ring colours are as follows: Tdark, black; 
Tbio, red; Tchem, green; and Tclin, blue. b | TDL distribution across protein families, coloured by TDL category. Data show 3,644 
proteins that have a confirmed disease association according to the Online Mendelian Inheritance in Man (OMIM) 
database. The enzyme category excludes kinases, which are considered separately. GPCR, G protein-coupled receptor.
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Because the above criteria are difficult to implement 
by automation, a previous analysis carefully curated 
MoA data from approved drug labels as well as primary 
literature, based on a rigorous definition of a drug tar-
get9. This ongoing process, performed in parallel by three 
teams, is anticipated to improve our ability to link drug 
responses to genetic variation and to help us understand 
the molecular basis of clinical efficacy, safety and adverse 
events. The interplay between target tissue expression 
under disease-specific conditions and the local concen-
tration of the drug or its active metabolites at the rele-
vant disease site is often difficult to ascertain, which is 
why we attributed a higher weight of evidence to data 
derived from multiple drugs belonging to the same ther-
apeutic class. Indeed, we anticipate that efficacy target 
annotations will become more precise as our capability 
to colocalize target, disease and drug increases.
From this analysis, Tclin currently consists of ~600 
protein targets9, which is at the lower end of the orig-
inal estimate of between 600 and 1,500 targets for the 
intersection between proteins in the druggable genome 
and disease-modifying genes by Hopkins and Groom20 
(note, however, that Tclin includes targets of biologic 
drugs as well as small molecules, while the estimate was 
for small-molecule drug targets only20). So far, proteins 
in the Tclin category thus represent only a small fraction 
(3%) of the human proteome (FIG. 1a). From a com-
mercial perspective, it is also noteworthy that most of 
the global revenues of the pharmaceutical industry are 
derived from drugs that target a relatively small number 
of the proteins in the Tclin category (BOX 2; TABLE 2). The 
majority (259 or 79.7%) of these targets are single pro-
teins, whereas 39 (12%) are complex multiprotein tar-
gets. Only 25 targets (8.3%) are comprised of multiple 
proteins for non-selective drugs; these include the mus-
carinic, α-adrenergic and oestrogen receptors, as well as 
cyclooxygenases and histone deacetylases.
Among the factors contributing to the small frac-
tion of each major protein family in Tclin so far, one 
factor is that not all members of a protein family have 
drug- compatible or ligandable21 binding sites; for 
example, some nuclear receptors lack an (endogenous) 
ligand-binding domain or do not appear to be amenable 
to small-molecule perturbation. Another factor is that 
not all proteins can (or will) alter the course of disease via 
therapeutic intervention, perhaps in some cases owing to 
our lack of understanding of the underlying pathology.
Kubinyi pointed out that single proteins combine 
in vivo in ways that could lead to many more drug 
target combinations across multiple pathways — that 
is, a ‘druggable proteome’ (REF. 22) — and there is now 
experimental evidence that alternative splicing, post- 
translational modification and heterogeneous oligomers 
produce functional isoforms with different interaction 
profiles, which may further result in increased diver-
sity of the proteome23. It is also important to note that 
for many drugs, the precise MoA and contributing 
molecular targets remain cryptic, especially when poly-
pharmacology (the simultaneous modulation of multiple 
targets by drugs) occurs. Shedding light on this would 
require data completeness24, namely, experiments across 
all proteins, in relevant physiological conditions, for all 
approved drugs. This remains a resource-intensive and 
costly task, which was partially accomplished25 by the 
NIH Molecular Libraries Initiative26.
Tchem proteins. Assignment to Tchem is based on com-
pound activity thresholds originating from binding 
experiments for small molecules (Supplementary 
Figure S2). Selectivity, though important both in vivo 
and in vitro, could not be factored in for all Tchem targets 
(Supplementary Box S6 and Supplementary Table S7). 
Because, by definition, Tclin attribution requires support-
ing evidence for the MoA, many proteins known to inter-
act with approved drugs, even with high affinity, remain 
in the Tchem category. Additional bioactivity data from, 
for example, patent literature and papers currently not 
indexed in ChEMBL may progress more targets to Tchem.
Many compounds that have reported activity against 
Tchem targets are also candidate drugs undergoing clini-
cal trials. Based on an in-depth analysis of clinical trial 
data combined with data from ChEMBL, PubMed, the 
Table 1 | Current distribution of TDL categories by protein family for the druggable genome
Target class All Tclin Tchem Tbio Tdark
GPCRs (non-olfactory) 406 96 113 145 52
Olfactory GPCRs 421 0 0 8 413
Kinases 634 50 390 163 31
Ion channels 355 126 44 150 35
Nuclear receptors 48 18 19 11 0
Transporters 473 26 46 287 114
Transcription factors 1,400 0 27 866 507
Epigenetic proteinsa 280 12 53 178 37
Enzymesb 4,146 186 493 2,607 860
Others 11,957 87 217 6,671 4,982
Total 20,120 601 1,402 11,086 7,031
GPCR, G protein-coupled receptor; TDL, target development level. aIncludes 40 transcription factors not already counted with 
those in the transcription factor category. bExcludes kinases.
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IUPHAR Guide to Pharmacology27 and ChemIDplus, we 
mapped 144 Tchem proteins to 356 clinical (phase I–III 
trial) candidates, for a total of 701 unique target–clinical 
candidate pairs. For 175 (25%) of these pairs, therapeutic 
indication data extracted from ChEMBL highlight the 
different distribution among protein families (TABLE 3). 
Most targeted proteins are kinases (93 unique enzymes), 
followed by GPCRs (31 unique receptors) and ion chan-
nels (13), with seven targets from other families, which 
is similar to the prior observation that most clinical 
candidates target the most druggable target families28. 
Analysis of the target–clinical candidate subset in which 
anticipated therapeutic indications are available shows 
that most of the kinase-targeting clinical candidates are 
aimed at oncology applications, whereas GPCRs and ion 
channel-targeting clinical candidates are aimed at central 
nervous system disorders.
As noted above, target druggability is frequently esti-
mated based on the ability to bind to small molecules20, 
and expectations of druggability typically diminish as 
the size of the binding pocket increases, with affinity 
and selectivity being major concerns. The challenge is 
even greater when the binding pocket is shallow and 
highly exposed to a solvent or when the therapeutic 
strategy involves disrupting the interaction between the 
targeted protein and other proteins. One approach to 
evaluating druggability is to focus on protein domains 
mined from the InterPro database29 and then to prior-
itize proteins that contain domains known to interact 
with approved drugs20 or bioactive small molecules30. 
Others have explored target druggability by evaluating 
side-effect similarity for known drugs31 or by perform-
ing combined chemical and target similarity queries32, 
followed by experimental confirmation of novel drug 
targets derived from clinical observation or computa-
tion. It is possible that induced binding sites in proteins 
in which a druggable pocket is not initially found may 
enable them to be targeted with drug-like small mole-
cules, but identifying these binding sites with structural 
approaches is likely to be challenging, and phenotypic 
screens may be more useful.
An emerging approach harnessing so-called PROTACs 
(proteolysis-targeting chimaeras) may help substantially 
in addressing the issue of undruggability33, at least for 
proteins that are capable of selectively binding a small- 
molecule ligand, although not necessarily at a typical 
binding site34. Essentially, this strategy harnesses the endo-
genous ubiquitin– proteasome system to promote targeted 
degradation of desired proteins following binding of the 
PROTAC35; the mechanism for ternary ligase–PROTAC–
target complex activation has been recently elucidated36. 
This technology may also be subcellular location-specific, 
which could be an additional advantage in some (but not 
other) cases. However, the oral bioavailability of PROTAC 
molecules may be constrained by their size.
Spotlight on Tbio and Tdark
A critical effort in addressing the knowledge deficit about 
Tbio and Tdark proteins is being undertaken by the Monarch 
Initiative37, which relies on informatics methods to iden-
tify phenotypically relevant disease models in research 
and diagnostic contexts based on integrated model organ-
ism and clinical research data. One of the main sources 
for the Monarch Initiative is phenotype data from the 
International Mouse Phenotype Consortium (IMPC), 
which was set up to generate and pheno typically char-
acterize mouse knockout lines. Their recent analysis of 
1,751 unique gene knockouts found that human disease 
genes are enriched for essential genes38.
The IDG KMC incorporates gene-centric mouse phe-
notype data and maps these data to the respective human 
orthologues. IDG coordinated with IMPC production 
centres to prioritize production of knockout mouse 
strains for druggable genes. As of November 2017, 568 
new knockout strains had been produced: 166 GPCRs, 
141 ion channels, 238 kinases and 23 nuclear receptors 
(see Supplementary Table S8). When ignoring olfactory 
GPCRs, these represent a little more than one-third of 
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Figure 2 | Patterns of target development level distribution across different data: 
visualizing the knowledge deficit. a | The three criteria used in establishing the target 
development level are to the left, and their independent validation by four other data 
types are to the right. For PubMed abstracts, Gene Reference Into Function (RIF) 
annotations, antibodies, Gene Ontology, R01 grants and patents, the score for each 
target is the count of those entities associated with the target, normalized between 0 
and 1. The values for the Harmonizome data availability score were computed differently, 
as described in the main text. See FIG. 1 for colour codes and Supplementary Table S4 for 
further details. b | Patterns of scientific curiosity: STRING database access counts by 
target development level (January–December 2016).
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Box 2 | Financial spotlight on the human proteome
Analyses of drug sales focus on pharmaceutical products95 and the 
companies authorized to market them96. Here, we ask a target-centric 
question — what are the most financially valuable therapeutic targets — 
by exploring IMS Health (now known as IQVIA) data from their MIDAS™ 
platform. We used IMS Health MIDAS drug sales data from 75 countries 
covering Europe, North America, Australia and Japan, aggregated for the 
2011–2015 period. MIDAS tracks products from most therapeutic classes, 
estimating product volumes, trends and market share through retail and 
non-retail channels. We chose quinquennial aggregation over annual sales 
data as it diminishes the importance of factors less relevant to this analysis, 
such as fluctuations in currency exchange rates. Because active 
ingredients lose patent coverage and become generic, annual sales figures 
can abruptly drop from one year to the next.
After excluding traditional medicines, including botanicals and  
animal products, the MIDAS set comprised 51,095 unique pharmaceutical 
products, including small molecules and biologics. As most anti-infective 
and antiparasitic drugs target non-human proteins (with the notable 
exception of maraviroc, which targets the host (human) CC-chemokine 
receptor type 5 (CCR5)), we removed these drugs because their targets are 
outside of the scope of this analysis. The remainder were mapped to 1,182 
active pharmaceutical ingredients (APIs) from DrugCentral10, which were 
first normalized by the number of APIs per pharmaceutical formulation, 
then by the number of manually curated mechanism of action (MoA) 
targets9 per API. Thus, we used 581 Tclin proteins and 1,096 APIs, a subset of 
the 893 human and pathogenic biomolecules through which 1,578 
previously analysed approved drugs act9.
By linking global drug sales data to drug targets, we sought to 
assess a snapshot of their commercial value and to evaluate the 
market value of human MoA targets. The top 20 MoA 
targets ranked by aggregated sales data, together with 
National Institutes of Health (NIH) R01 funding for 
the same period, are shown in TABLE 2. The entire 
set covers 325 drug targets, comprising 
581 Tclin proteins, totalling over US$3,417 
billion in global drug sales 
(Supplementary Table S10). These data 
indicate that the cytokine tumour 
necrosis factor (TNF) is the most 
valuable target, and cytokines are 
the only target class comprised 
entirely of biologic drugs in this 
analysis for the 2011–2015 period. 
G protein-coupled receptors 
(GPCRs) are the most valuable 
class of druggable targets, with 
total aggregated sales nearing 
$917 billion over the 5‑year 
period. This spotlight covers 72 
of the 108 druggable GPCRs 
reviewed elsewhere97. Kinases 
($263 billion, with 45 drugs acting 
on 43 targets) and cytokines 
($242 billion, with 17 drugs acting on 
12 targets) are the only two target 
classes with an extremely active ratio 
of ongoing versus completed projects, 
particularly for emerging mechanism–
indication pairs98. Finally, combining 
financial data with targets organized by family 
and Anatomical, Therapeutic and Chemical (ATC) 
classification system level 2 codes shows that the 
top revenue categories are antineoplastics and 
immunomodulators, followed by nervous system 
targets (see box figure; a larger version is available as 
Supplementary Figure S11; see also Supplementary Table S10).
The commercial outcomes of target selection and product-led validation 
can also be analysed with respect to research funding. NIH RePORTER data 
(see the NIH ExPORTER website) were processed using the same 
text-mining methods described earlier for FIG. 2. During the same period, 
2011–2015, the NIH funded 42,924 R01 grant applications, at a total cost of 
$32 billion. These projects discuss up to 7,851 human proteins (see 
Supplementary Table S10). For example, R01 grants associated with 
oestrogen receptors were awarded $101 million, compared with $50 billion 
in sales earned by 18 drugs acting through oestrogen receptors during that 
same period (TABLE 2). Some targets, having over 30 drugs each, are also 
top-earning and well funded, for example, the μ-opioid (OPRM1) and the 
glucocorticoid (NR3C1) receptors. Other top-earning targets with over  
30 drugs each, such as the β2 adrenergic receptor and cyclooxygenase 1, 
are not as well funded. We found no relationship between MIDAS global 
drug target sales and NIH R01 funding during the 2011–2015 period, even 
when factoring in the number of APIs per target. Overall, $4.2 billion was 
awarded to study 496 Tclin proteins, representing 13% of the R01 budget and 
6% of all R01-funded proteins. Another 615 proteins (485 Tbio and 67 Tdark) 
had just one funded R01 project dedicated to their study during 2011–2015, 
and 8,857 proteins were not associated with any NIH funding for this  
time frame. AT1 receptor, angiotensin II type 1 receptor; COX2, 
cyclooxygenase 2; DPP4, dipeptidyl peptidase 4; HMG-CoA, 
3-hydroxy-3-methylglutaryl-CoA.
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Table 2 | Financial (sales and NIH funding) activity for the top 20 mechanism-of-action targets
Target Target 
class
Top two drugs Number 
of APIs
MIDAS 
global sales, 
2011–2015 
per target 
(US$)
NIH R01 
funding, 
2011–2015 
per target 
(US$)
Target 
type
Protein 
count
TNF Cytokine Adalimumab and 
etanercept
5 163 billion 165 million Single 1
INSR Kinase Insulin glargine 
and insulin 
aspart
7 144 billion 2 million Single 1
NR3C1 NHR Fluticasone 
propionate and 
budesonide
36 143 billion 52 million Single 1
HMGCR Enzyme Rosuvastatin and 
atorvastatin
8 123 billion 1 million Single 1
H+/K+-ATPase Transporter Esomeprazole 
and omeprazole
10 118 billion 5 million Complex 2
AGTR1 GPCR Valsartan and 
olmesartan 
medoxomil
9 100 billion 17 million Single 1
ADRB2 GPCR Salmeterol and 
salbutamol
36 90 billion 8 million Single 1
OPRM1 GPCR Oxycodone and 
fentanyl
34 88 billion 51 million Single 1
COX2 Enzyme Paracetamol and 
diclofenac
40 84 billion 8 million Single 1
DRD2 GPCR Aripiprazole and 
quetiapine
48 75 billion 17 million Single 1
Muscarinic 
acetylcholine 
receptors
GPCR Tiotropium 
bromide and 
solifenacin
40 64 billion 65 million Multiple 5
SLC6A4 Transporter Duloxetine and 
escitalopram
26 59 billion 46 million Single 1
HTR2A GPCR Aripiprazole and 
quetiapine
27 58 billion 13 million Single 1
L-Type 
calcium 
channels
Ion 
channel
Amlodipine and 
nifedipine
23 57 billion 21 million Complex 3
SLC6A2 Transporter Duloxetine and 
methylphenidate
36 56 billion 5 million Single 1
VEGFA Cytokine Bevacizumab 
and ranibizumab
4 55 billion 162 million Single 1
HRH1 GPCR Olopatadine and 
cetirizine
56 54 billion 1 million Single 1
Interferon α–β 
receptor
Membrane 
receptor
Interferon β-1a 
and interferon 
β-1b
5 51 billion 7 million Multiple 2
Voltage-gated 
sodium 
channels
Ion 
channel
Lidocaine and 
lamotrigine
39 51 billion 40 million Multiple, 
complex
10
Oestrogen 
receptors
NHR Ethinyloestradiol 
and oestradiol
18 50 billion 101 million Multiple 2
Targets are ranked by aggregated API sales data. The number of drugs is the number of MoA-target-associated APIs used in 
this data set. Target type: single, one protein; multiple, more than one target; complex, more than one protein per target. 
Protein count, number of proteins associated with that target. ADRB2, β2-adrenoceptor; AGTR1, AT1 receptor; API, active 
pharmaceutical ingredient; HMGCR, hydroxymethylglutaryl-CoA reductase; DRD2, dopamine D2 receptor; GPCR, G 
protein-coupled receptor; HRH1, histamine H1 receptor; HTR2A, serotonin 5-HT2A receptor; INSR, insulin receptor; MoA, 
mechanism of action; NHR, nuclear hormone receptor; NIH, National Institutes of Health; NR3C1, glucocorticoid receptor; 
OPRM1, μ-opioid receptor; COX2, cyclooxygenase 2; SLC6A2, sodium-dependent noradrenaline transporter; SLC6A4, 
sodium-dependent serotonin transporter; TNF, tumour necrosis factor; VEGFA, vascular endothelial growth factor A.
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the druggable genes in these protein families. Phenotype 
data are available for 80% of these strains, with abnor-
malities detected in numerous biological systems, 
including those related to development, immune func-
tion, metabolism and behaviour. These IMPC strains 
provide evidence for biological systems that may be 
affected when a drug targets a gene with little-known 
function.
Of the 119 Tdark genes (51 GPCRs, 36 ion channels 
and 32 kinases) submitted by IDG to IMPC, 45 mouse 
lines were produced, with 41 phenotypes observed. 
For example, knockouts of the Tdark kinase gene Alpk3 
have increased embryonic and perinatal lethality, with 
the surviving adults displaying severe heart defects 
(see Further information). Of 482 Tbio genes submitted 
by IDG (135 GPCRs, 133 ion channels, 200 kinases and 
14 nuclear receptors), 184 mouse lines were produced, 
with 145 phenotypes observed. For example, knock-
outs of the Tbio GPCR gene Adgrd1 display reproductive 
defects, such as female infertility, and skeleton pheno-
type defects, such as decreased bone mineral density (see 
Further information).
Among 2,788 genes phenotyped in mice at the IMPC, 
953 have at least one significant behavioural, neuro logical 
or other nervous system-related phenotype observation. 
Target Central Resource Database (TCRD) data from the 
GWAS Catalog39, OMIM11 and text-mined DISEASES13 
databases confirmed human disease phenotypes for 191 
(20%) of these 953 genes, ranging from neurological (for 
example, seizure disorders) to cognitive (for example, 
tauopathy) and psychotic affective disorders. Because 
only 9 of the 953 genes lack confirmed expression in any 
of the 34 neuro-related tissues tracked by IDG KMC (for 
example, GTEx40,41, HPA42 and HPM43), these data sug-
gest that the remaining 80% of this set have the potential 
to be associated with human neurobehavioural pheno-
types, paving the way for new research avenues in this 
direction (see Supplementary Table S8). Production of 
IMPC strains is set to continue for several more years, 
and so further knockout strains for druggable genes and 
their phenotype data are anticipated.
To further explore the characteristics of Tdark and Tbio 
proteins, we analysed their distribution in the L1000 gene 
set, as annotated in TCRD (Supplementary Table S3). 
L1000 is a set of 978 landmark genes that have been 
selected for their ability to predict a large portion of the 
total variability seen in large sets of microarray exper-
iments. The proportion of Tdark proteins in the L1000 
set (79 of 978; 8%) is substantially smaller than would 
be anticipated based simply on the a priori distribution 
of Tdark proteins (which make up 35% of the proteome), 
whereas Tbio targets (671 of 978; 69%) are more common 
than expected, as these make up 53% of the proteome. 
The proportions of Tclin proteins (41 of 978; 4%) and 
Tchem proteins in the L1000 set (187 of 978; 19%) are also 
higher than expected, as these make up 3% and 7% of the 
proteome, respectively. The L1000 TDL distribution data 
support the existence of a knowledge deficit.
To some extent, the data on Tbio and Tdark suggest 
a causality dilemma: are Tdark proteins underfunded 
because there is no scientific interest in this category, or 
is the lack of knowledge perpetuated by lack of funding? 
Although our data do not allow us to establish a causal 
relationship, we suggest that the absence of high-quality, 
well-characterized molecular probes is a root cause for 
this situation. Lack of tools leads to lack of interest, and 
lack of interest diminishes the probability of such tools 
being developed. A bibliometric evaluation by Edwards 
and colleagues2 examined how many newly sequenced 
proteins from several protein families were the subject of 
new studies 10 years after the completion of the human 
genome sequencing project. This analysis concluded 
that the process of druggable target selection is con-
servative and incremental and that limited progress 
has been observed with respect to understanding newly 
discovered proteins.
“If you don’t know very much to begin with, don’t 
expect to learn a lot quickly” (REF. 44). Anecdotal evi-
dence (summarized in TABLE 4) suggests that it is pos-
sible for proteins to migrate from Tdark to Tclin within 
12–20 years. Data on the six protein targets highlighted 
indicate that proteins for which little information was 
available two decades ago (effectively Tdark) became 
attractive from a drug discovery perspective follow-
ing key papers, namely, deorphanization and protein– 
disease association studies. Five of these six targets are 
modulated by at least one approved drug, which places 
them in the Tclin category.
Table 3 | Summary of clinical candidates (phase I–III) with activity against Tchem proteins
Disease category GPCRs Ion channels Kinases Other
Cancer – – 41 (35) 1 (1)
Central nervous system 
disorders
7 (14) 8 (5) – –
Inflammation and immune 
disorders
5 (5) 1 (1) 5 (5) –
Respiratory disorders 3 (7) 1 (1) 1 (1) –
Metabolic disorders 3 (2) – – –
Other 3 (3) – 7 (6) 1 (1)
Unmapped 28 (58) 11 (23) 87 (175) 5 (14)
Numbers in brackets indicate the number of unique clinical candidates. GPCRs, G protein-coupled receptors.
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Successful ‘promotions’ across classes, such as those in 
TABLE 4, are currently rare. We expect the rate of knowl-
edge accumulation for Tdark proteins to be low, at least 
initially. Well-studied proteins require multiple layers of 
management for diverse, rich sets of data, with informa-
tion and knowledge stemming from corpora such as bio-
medical literature, patents and clinical trials. A paucity of 
data and lack of information for understudied proteins 
(Tbio and Tdark) affect both knowledge management and 
the decision-making process with respect to experimen-
tal planning, what research questions need to be asked 
(and in what order) and which methods may be better 
suited for each task. For example, we examined access 
counts for human proteins in STRING18 during 2016 
(FIG. 2b). ‘Counts by name’ represents users that access 
the STRING website and type in a gene symbol. ‘Counts 
by link’ represents users accessing the network for a gene 
in STRING by linking to it from another resource (for 
example, GeneCards45 or UniProt15). Whereas ‘Counts 
by link’ shows a more comprehensive method to access 
the entire proteome, it also suggests that Tdark proteins 
have a lower probability of being recognized (input) by 
gene name. These data show a pattern similar to that 
observed in FIG. 2a: Tdark proteins are less likely to be 
the subject of scientific curiosity, which is a reflection 
of funding patterns and an overall lack of information 
and molecular probes. Indeed, the paucity of antibodies 
and small molecules (criteria that help define Tbio and 
Tchem, respectively) that could be used to interrogate Tdark 
proteins diminishes our ability to subject Tdark proteins 
to scientific inquiry.
Genomic and proteomic responses following radia-
tion therapy are also understudied. One in vitro study46 
suggested that as many as one-third of the 10,174 genes 
examined in immortalized B cells following ionizing 
radiation are radioresponsive (GSE26835 column46 in 
Supplementary Table S3). Of the 447 genes with signif-
icant fold changes in the GSE26835 set, only 26 are Tclin 
and 61 are Tchem, whereas the majority (268 Tbio, 92 Tdark) 
are understudied (see also Supplementary Box S5).
As many as 3,644 proteins have significant disease 
(confirmed OMIM11 phenotype) associations. Given 
their TDL assignments (335 Tclin, 543 Tchem and 2,766 
Tbio), we examined the distribution of the TDL in rela-
tion to druggable protein family categories (FIG. 1b). It 
appears that Tbio–disease associations are quite rare for 
druggable families such as nuclear receptors, ion chan-
nels and GPCRs, as these families are more likely to be 
in the Tclin or Tchem category. Instead, Tbio assignments 
are quite frequent for transcription factors, epigenetic 
targets, transporters and unassigned protein families. 
The exception among druggable families are olfactory 
GPCRs, which appear to attract less interest from drug 
discovery programmes, despite some of these GPCRs 
being linked to metabolism and ageing47.
Concerted efforts focused on an entire target 
class have sometimes led to new drugs. For example, 
GlaxoSmithKline (GSK) had a comprehensive pro-
gramme aimed at finding new ligands and characteriz-
ing the biology of nuclear receptors48. New insights into 
bile acid metabolism49 and xenobiotic transcription of 
cytochrome P450s50, mediated by nuclear receptors, 
were described. A bile acid receptor (FXR) agonist has 
reached the market since this programme started: obet-
icholic acid (Ocaliva), which was discovered by GSK 
in collaboration with the University of Perugia51 and 
subsequently developed by Intercept Pharmaceuticals. 
Currently, several FXR agonists are in clinical develop-
ment52. Choosing the appropriate proteins as drug targets 
remains a complex process, where scientific factors need 
to be balanced against commercial factors (such as com-
pany investors and medical insurance companies) and 
societal factors (such as physicians and patients), as well 
as legal factors (such as the requirements of regulatory 
agencies)1.
Spotlight on G protein-coupled receptors
GPCRs are membrane-bound, cell-surface receptors that 
transduce signals via interactions with hetero trimeric G 
proteins, arrestins and other cellular transducers53,54. 
Table 4 | Examples of successful attempts of targeting the dark genome
Gene name Relevant 
study (year)
Study type and 
reference
Citation 
counta
API name Therapeutic 
indication
Market 
approval (year)
LEPR 1995 Receptor 
deorphanization99
4,100 Metreleptin Lipodystrophy 2014
SMO 1998 Protein–disease 
association study100
1,195 Vismodegib Basal cell 
carcinoma
2012
S1PR1 1998 Receptor 
deorphanization101
968 Fingolimod Multiple sclerosis 2010
HCRTR1 and 
HCRTR2
1998 Receptor 
deorphanization102
4,608 Suvorexant Insomnia 2014
PCSK9 2003 Protein–disease 
association study103
1,840 Evolocumab Hyper-
cholesterolaemia
2015
GHSR 1999 Receptor 
deorphanization104
8,248 Anamorelinb Cachexia Successful phase 
III clinical trial105
API, active pharmaceutical ingredient; GHSR, ghrelin receptor; HCTR1, orexin receptor type 1; LEPR, leptin receptor; PCSK9, 
proprotein convertase subtilisin/kexin type 9; S1PR1, sphingosine 1-phosphate receptor 1; SMO, smoothened homologue. 
aCitation count for the ‘relevant study’ reference, according to Google Scholar, as of 28 December 2017. bThe European Medicines 
Agency refused marketing authorization for anamorelin in September 2017. 
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Alterations in GPCR signalling are implicated in the 
pathogenesis and treatment of neuropsychiatric55, 
immunological56, gastrointestinal57,58, cardiac59, renal, 
hormonal, infectious60 and many other disorders53,54. 
GPCRs represent the largest family of druggable targets 
in the human genome9, with between 20% and 30% of 
approved drugs acting on them53,54.
The number of publications per GPCR and the num-
ber of chemicals associated with that GPCR in ChEMBL 
were examined61 to determine which of the druggable, 
non-olfactory GPCRs are understudied: less than 100 
citations and less than ten ChEMBL compounds define 
understudied, uninterrogated GPCRs. The number of 
publications, similar to the fractional PubMed publi-
cations count13, does not take into account large-scale 
(many proteins per paper) analyses. Counting ChEMBL 
compounds, a quantitative criterion similar to Tchem 
assignments, does not consider bioactivity values. 
However, this independent analysis validates the more 
general TDL criteria with respect to GPCR biological 
functions and corresponding chemical matter.
Tclin and Tchem G protein-coupled receptors. Currently 
827 GPCRs — including 421 olfactory GPCRs — are 
tracked by IDG KMC; of these, 96 are Tclin and 113 
are Tchem (none of which are olfactory). Slightly more 
than half of the non-olfactory GPCRs have annotated 
drugs and small molecules targeting them53,54,61; see 
also TABLE 1. A recent analysis indicates, however, that a 
handful of GPCRs — mainly biogenic amine, muscarinic 
and opioid receptors — represent the most abundantly 
targeted receptors for FDA-approved medications53,54. 
GPCRs also represent important off-targets for kinase 
inhibitors62,63, ion channel modulators64, anti- infectives65 
and other classes of drug-like molecules53,54. As with 
other druggable target classes, off-target actions within 
the GPCR class can be associated with severe and life- 
threatening side effects. For example, valvular heart 
disease is associated with anorectic agents, such as fen-
fluramine, and antimigraine medications, such as ergot-
amine, via serotonin 5-HT2B receptor agonism66. Recent 
successes in structure-guided and cheminformatics- 
driven drug discovery show promise for creating safer 
and more effective medications targeting GPCRs.
Tbio and Tdark G protein-coupled receptors. Although 52 
non-olfactory GPCRs are categorized as Tdark, the avail-
ability of new screening platforms to discover chemical 
matter for these GPCRs has begun the process of illumi-
nation64,67,68. Of 62 GPCRs for which significant pheno-
type calls have been reported by IMPC (Supplementary 
Table S8), 24 are Tbio and 7 are Tdark; of these, 15 are asso-
ciated with neurological and behavioural phenotypes. 
Including olfactory GPCRs, 618 proteins are classified 
as Tdark or Tbio; of these, 126 non-olfactory GPCRs and 
51 olfactory GPCRs have significant associations with 
human diseases via OMIM, GWAS and text mining. 
Whereas the majority of these associations (nearly 59%) 
stem from text mining69, 48 GPCRs have confirmed 
associations from at least two information channels. For 
example, Adgrb2-mutant mice (Tbio) showed significant 
antidepressant- like behaviour compared with wild-type 
mice70, whereas the association71 between schizophrenia 
and Fzd3 mutants (Tbio) remains controversial72,73.
Spotlight on protein kinases
Tclin and Tchem kinases. The ~600-member human 
kinome (Supplementary Table S3) is made up of pro-
tein kinases, in addition to metabolic and lipid kinases, 
and is highly druggable using both competitive and 
allosteric small-molecule inhibitors. However, the func-
tions of about one-third of the kinases in this family are 
poorly defined or unknown. The 634 human kinases 
were categorized as follows: Tclin, N = 50; Tchem, N = 390; 
Tbio, N = 163; and Tdark, N = 31 (TABLE 1). Tclin kinases 
are not exclusively protein kinases, and the number of 
FDA-approved small-molecule kinase inhibitors varies 
depending on inclusion criteria. Wu and colleagues74 
found 38 small-molecule protein kinase inhibi-
tors. Based on DrugCentral, we found 50 approved 
kinase inhibitors, including 40 small-molecule pro-
tein kinase inhibitors, of which 32 are FDA-approved, 
one FDA-approved protein kinase activator (ingenol 
mebutate) and the phosphoinositide 3-kinase subunit-δ 
(PIK3CD) small-molecule inhibitor idelalisib, which is 
also FDA-approved. An additional seven FDA-approved 
antibodies target the receptor tyrosine kinases human 
epidermal growth factor receptor 2 (HER2; also known as 
ERBB2), epidermal growth factor receptor (EGFR), vas-
cular endothelial growth factor receptor 2 (VEGFR2) and 
platelet- derived growth factor receptor-α (PDGFRα), 
and there is also an FDA-approved HER2-targeting 
antibody–drug conjugate, trastuzumab emtansine (see 
Supplementary Table S9).
Tbio and Tdark kinases. A number of Tbio and Tdark kinases 
are known to interact with FDA-approved multikinase 
inhibitors. According to data in DrugCentral, sorafenib 
inhibits 114 kinases, of which only 9 are associated MoA-
related targets, whereas sunitinib inhibits 263 kinases, of 
which 9 are MoA-related targets. Given the current state 
of kinase inhibitor chemistry, it is very likely that Tbio and 
Tdark kinases can be effectively therapeutically targeted 
with highly selective small- molecule inhibitors. Some of 
the characteristics shared by understudied Tbio and Tdark 
kinases include poorly defined integration of the kinase 
in signalling networks, poorly defined function and reg-
ulation, lack of activation-loop phospho-antibodies or 
immunohistochemistry-grade antibodies, and lack of 
selective chemical tools for functional characterization. 
Primary tools for knockout and/or altered expression 
are RNA interference (RNAi) and CRISPR–Cas9, and 
cDNAs for overexpression; kinase knockout or altered 
expression rarely provides readily assayable phenotypes 
(for example, growth, migration, apoptosis or in vivo 
function in mouse organ physiology). Currently, the 
IMPC has targeted 238 kinases with 114 knockouts hav-
ing a significant phenotype; of the latter, 22 are of current 
interest for phase 2 of the IDG programme.
Many Tchem, Tbio or Tdark kinases are altered in expres-
sion or mutated in TCGA. TABLE 5 shows ten Tbio or Tdark 
kinases whose amplification is observed in the TCGA 
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database, together with their RNA expression in tri-
ple-negative breast cancer (TNBC) cells. These under-
studied kinases are frequently altered in breast cancer. 
The potential increased expression of many kinases in 
primary human tumours suggests these understudied 
kinases have important functions for the tumour cell 
phenotype that have not been characterized to date. 
These represent unexplored kinases with possible 
therapeutic utility.
The potential therapeutic importance of Tbio and Tdark 
kinases in the kinome is highlighted by a recent clinical 
study that assessed the response to trametinib, a MEK1 
and MEK2 inhibitor, in TNBC patients75. Pretreatment 
needle biopsies and surgical tumour resections follow-
ing 7-day trametinib treatment were used for RNA 
sequencing (RNA-seq) to analyse tumour transcriptomic 
changes in response to the drug. Pretreatment biopsies 
matched to post-treatment surgical specimens showed 
overall concordance of the transcriptional kinase 
response to trametinib, with FRK (Tchem) exhibiting the 
highest mean increase and cytoplasmic BMX (also Tchem) 
exhibiting the highest mean decrease among patients 
in response to a 7-day drug treatment. Among the 
kinases transcriptionally altered in the TNBC tumours 
were several understudied kinases, including MRCK-γ 
(also known as CDC42BPG), PRKACB, STK32B and 
leukocyte tyrosine kinase receptor (LTK). These find-
ings demonstrate that in TNBC tumours in patients, 
members of the understudied Tbio and Tdark kinome are 
co-regulated transcriptionally with kinases from the Tclin 
and Tchem category, in a dynamic adaptive response to 
targeted inhibition.
Spotlight on ion channels
Ion channels mediate signalling within cells, between 
cells, and between cells and their environment. Defects in 
ion channels underlie many major disorders in humans, 
also known as channelopathies, including neuronal 
disorders76, diabetes77 and heart failure78. This makes 
ion channels an attractive target class for drug develop-
ment. Ion channels are mostly heteromeric complexes 
that require optimal interactions with ligands at specific 
locations. Currently, 355 ion channel pore-forming and 
auxiliary subunits are tracked by IDG KMC (TABLE 1; 
Supplementary Table S3). About 100 ion channel modula-
tors, including auxiliary subunits, are reported, but to our 
knowledge, a systematic list of cell type-specific auxiliary 
subunits for all ion channels is not available.
Tclin and Tchem ion channels. Many drugs are known to 
bind to ion channels. There are 217 drugs annotated in 
DrugCentral10 as acting through 125 (Tclin) ion channels 
for the MoA9. The number of drugs increases to 497 
when querying how many drugs are known to interact 
with ion channels outside of the MoA-related constraint. 
Some of these interactions are likely to be responsible for 
side effects such as cardiac toxicity. An accurate under-
standing of MoA and side-effect assignment at the target 
(molecular) level is required if we are to improve upon 
available drugs. For example, the anaesthetic ketamine, 
which has been postulated to act as a noncompetitive 
N-methyl-d-aspartate (NMDA) antagonist79, has been 
used off-label as an antidepressant80. However, in-depth 
analysis of the antidepressant effects of ketamine found 
that its active metabolite (2R,6R)-hydroxynorketamine 
(HNK) does not block the NMDA receptor. Instead, 
HNK displays sustained activation of α-amino-3- 
hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) 
receptors and lacks ketamine-related side effects81. 
This may pave the way for the development of novel, 
rapid-acting antidepressants. It is therefore conceivable 
that some ion channels currently categorized as Tclin or 
Tchem are in need of further illumination with respect to 
MoA and drug specificity. Indeed, the low bioactivity 
cut-off criterion for ion channels (≤10 μM) in Tchem (see 
also Supplementary Figure S2) may need revision, given 
that older drugs continue to reveal unexpected modes 
of action.
Table 5 | Understudied kinases that are frequently altered in breast cancer
Gene name Protein name TDL SUM159 
averagea
Alteration 
frequencyb 
(%)
Kinase family
TRIB1 Tribbles homologue 1 Tbio 342 24 CAMK
RPS6KC1 Ribosomal protein S6 kinase δ1 Tdark 463 23 Other
UHMK1 Serine/threonine-protein kinase Kist Tbio 1,308 23 Other
NRBP2 Nuclear receptor-binding protein 2 Tdark 350 21 Other
PIP5K1A Phosphatidylinositol 4-phosphate 5-kinase type 
1-α
Tbio 2,246 19 Metabolic
CDK12 Cyclin-dependent kinase 12 Tbio 3,148 14 CMGC
MAP3K1 Mitogen-activated protein kinase kinase kinase 1 Tbio 455 11 STE
STRADA STE20-related kinase adapter protein-α Tbio 464 9 STE
BCKDK (3-methyl-2-oxobutanoate dehydrogenase 
(lipoamide)) kinase, mitochondrial
Tbio 1,087 6 Atypical
EEF2K Eukaryotic elongation factor 2 kinase Tbio 1,176 6 Atypical
aExpression levels in SUM159PT claudin-low triple-negative breast cancer (TNBC) cells. bAlteration frequency in breast cancer from 
The Cancer Genome Atlas (TCGA). TDL, target development level.
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Tdark ion channels. A relatively small number of ion 
channels (31) are categorized as Tdark (TABLE 1). Part of 
the difficulty in illuminating dark ion channels is the 
replication of physiological context and expression of 
proteins in the appropriate heteromeric, pore-forming 
functional complexes. Currently, there are no scalable 
systems available to study the localization of functional 
complexes. Moreover, most ion channels have paralogues 
that function redundantly. Gene redundancy increases 
the difficulty of revealing phenotype and precise localiza-
tion, both important elements for understanding physio-
logical functions other than ion channel activity. This 
considerably delays our progress in understanding ion 
channel function in vivo and their role in human health. 
Unlike GPCRs or kinases, neither pore- forming subunits 
nor auxiliary subunits share characteristic motifs. Lack 
of specific protein sequence motifs makes it difficult to 
flag candidate genes for further study, even with compu-
tational assertions. There could be other ion channels, 
which perhaps should be categorized as Tdark.dark, to reflect 
our complete lack of knowledge, even by computational 
means, regarding these proteins.
The list of ion channel pore-forming subunits, as well 
as auxiliary subunits, continues to grow. For example, 
leucine-rich repeat-containing protein 8 (LRRC8) heter-
omers form82 volume-regulated anion channels (VRACs), 
and ORAI proteins assemble to form83 calcium- release-
activated calcium channels (CRACs), whereas anoc-
tamins are olfactory calcium-activated chloride channels 
(CACCs)84. Currently, LRRC8B, LRRC8C and LRRC8D 
subunits are classified as Tdark, with the exception being 
the subunit LRRC8A (Tbio); ORAI1 is annotated as Tchem, 
wheras the ORAI2 and ORAI3 proteins are annotated as 
Tbio. With the exception of anoctamin 1 (Tclin), all other 
anoctamins are labelled Tbio. These, and all other Tdark 
proteins that lack computational assertions, are in need 
of systematic genomic-scale studies.
Conclusions
Modern medicine often employs artificial distinctions 
in terms of what and how biological systems are stud-
ied: segregated by organ (for example, ophthalmology 
and cardiology) or by disease (for example, oncology and 
infectious diseases), medical specialty separations carry 
over into the research arena, both in academia and indus-
try. This distinction breaks down in nature, as we are 
likely to observe the interplay between the same genes 
and pathways regardless of organ, albeit in a context- 
specific manner. These artificial divisions can prevent sci-
entists from achieving a translational, integrative view of 
gene and protein function. We suspect this to be another 
reason why funding to study Tdark proteins is scarce: for 
functionally enigmatic proteins, or the ‘ignorome’ (REF. 85), 
anticipating which organ, disease or phenotype is relevant 
may be far from trivial. To address this limitation, the 
NIH launched a series of high-risk programmes via 
the Common Fund resource, aimed to catalyse trans- 
disciplinary research. The IDG is one such Common 
Fund programme. The IDG programme’s ostensible 
goal is to encourage and track the illumination of rela-
tively understudied and unstudied parts of the genome. 
This implicitly requires the construction of a knowledge 
base objectively and in an unbiased manner, asserting 
what is currently believed to be true (a process that is 
explored metaphorically in a classic book by Italo Calvino, 
‘The Castle of Crossed Destinies’; see Supplementary Box 
S1). The IDG KMC enables us to quantitatively demon-
strate the existence of a knowledge deficit with respect to 
dark and understudied proteins, which underscores the 
need for basic science and its major role in illuminating 
gene functions and roles in human disease. The TDL clas-
sification scheme provides a convenient way to partition 
human targets that highlights the focus (or lack thereof) 
of science and drug discovery efforts on different targets. 
Through the use of the TDL groupings, we can highlight 
knowledge accumulation, as well as deficits, for a vari-
ety of target families, with a common theme being that 
while much is known, there remains a large fraction of the 
proteome that is understudied. The IDG KMC, by collat-
ing and linking a plethora of disparate and diverse data 
sources and data types, aims to shed light on these dark 
regions with the hope that researchers will be empowered 
to use the data and knowledge presented by the KMC to 
jumpstart research programmes on these targets.
Confirmed associations with a specific disease, or 
receptor deorphanization (TABLE 4), remain major incen-
tives to allocate resources and further study of Tdark 
proteins. As mentioned above, the only other deliber-
ate targeted effort to study Tdark proteins in addition to 
IDG is the IMPC. As of March 2017, mouse lines cor-
responding to 4,165 human genes have been produced, 
with phenotypes available, 2,788 of which have resulted 
in statistically significant phenotype calls. Of these 2,788 
proteins, 827 (436 Tdark) are not associated with any NIH-
funded grants between 2000 and 2015 (Supplementary 
Table S8). By contrast, only 120 of the 1,961 proteins with 
significant IMPC phenotype calls and that are associated 
with NIH funding are Tdark. It was Edgar Allan Poe who 
once said, “the enormous multiplication of books in every 
branch of knowledge is one of the greatest evils of this 
age, since it presents one of the most serious obstacles to 
the acquisition of correct information”. Poe’s 19th cen-
tury line of thought is remarkably apt in the context of 
current KMC activities, since the “acquisition of correct 
information” remains the largest challenge.
Another challenge relates to an area of knowledge 
largely neglected in the scientific literature: the large-scale 
capture of negative results. Due to confirmation bias8, 
scientists have a tendency to primarily publish success-
ful accounts of research. Although there are attempts to 
overcome this problem86, we are not aware of the exist-
ence of an unbiased, easy mechanism to capture negative 
results. The aphorism “absence of evidence is not evidence 
of absence” illustrates practical limitations of knowledge 
management systems: does lack of evidence imply that 
the study was conducted, but nothing was found, or does 
it imply (more often) that the measurement was not car-
ried out? Proper archiving of negative results (for example, 
“protein P is not expressed in cell type CT” or “gene muta-
tion Gm does not play a role in disease D”) would benefit 
the community at large and would improve our specific 
knowledge about proteins. However, such non-positive 
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facts fit poorly to current publishing and citation para-
digms. One possibility for archiving such statements could 
be nanopublications87, which would be amenable to large-
scale integration into systems such as TCRD–Pharos.
Finally, a key challenge faced by IDG KMC, and 
perhaps by other data analysts working in drug dis-
covery, is that of reliable predictions: when examining 
Tdark proteins in particular, experimentalists would like 
to know what experiment to do next, what phenotypic 
changes should be examined first and which pathway is 
relevant in a specific disease. These, and other similar 
questions, have yet to find a computer-driven, reliable 
answer. To paraphrase William Gibson, “The truth is 
already here — it’s just not very evenly distributed”.
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